Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naive Advanced Melanoma

By afschroeder • July 26, 2025

Ribas A, Milhem MM, Hoimes CJ, Amin A, Lao CD, Conry RM, Hunt JP, Daniels GA, Almubarak M, Shaheen M, Medina T, Barve M, Bishnoi S, Abdi E, Chisamore MJ, Guiducci C, Gomez-Romo J, Candia A, Gamelin E, Coffman RL, Janssen RS, Long GV. Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naive Advanced Melanoma. Clin Cancer Res. 2025 Jul 25. doi: 10.1158/1078-0432.CCR-25-0987. Epub ahead of print. PMID: 40711475.

Tags: Hematology/Oncology, Publications

Prevalence of chlamydial, gonococcal and syphilis positivity by anatomical site and sex via self-collected biospecimens using at-home testing kits among a large and diverse cohort of men and women enrolled in the MACS/WIHS Combined Cohort Study (MWCCS) in the USA

Mimiaga MJ, Tian J, Chiu I, Yonko EA, Noori G, Aziz N, Jamieson BD, Qian Y, Alcaide ML, Augenbraun M, Friedman MR, Kempf MC, Dionne-Odom[...]

Impact of postoperative FDG-PET/CT on adjuvant head and neck cancer treatment

Courtney PT, Juarez Casillas JE, Liu EY, Sim MS, Chau LW, Lopez-Chicas RE, St John MA, Abemayor E, Blackwell KE, Chhetri DK, Gopen QS, Kedeshian[...]

Datopotamab Deruxtecan-Associated Select Adverse Events: Clinical Practices and Institutional Protocols on Prophylaxis, Monitoring, and Management

Lisberg A, Huppert LA, Halmos B, Ledezma B, Soto-Romano V, Traina TA. Datopotamab Deruxtecan-Associated Select Adverse Events: Clinical Practices and Institutional Protocols on Prophylaxis, Monitoring,[...]